Research Article ISSN 2993-6799

Japanese Journal of Medical Research

Assessment of Safety and Dosage for Colonzak®: A Synbiotic Nutritional Supplement

Shypulin V[1], Hrytsak L[2] and Manolache M[3]*

[1]*Professor, Doctor of Medical Sciences, Head of the Department of Internal Medicine with a Course in Gastroenterology Bogomolets National Medical University, Kyiv, Ukraine.*
ORCID ID: 0000-0002-6780-130X.

[2]*Assistant Professor, Department of Surgery with a course in Hepatobiliary and Vascular Surgery, Bogomolets National Medical University, Kyiv, Ukraine.*
ORCID ID: 0000-0003-1779-8912.

[3]*Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.*
ORCID ID: 0000-0002-1811-3965.

***Correspondence:**
Manolache M, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Received: 15 Mar 2026; **Accepted:** 16 Apr 2026; **Published:** 27 Apr 2026

Citation: Shypulin V, Hrytsak L, Manolache M. Assessment of Safety and Dosage for Colonzak®: A Synbiotic Nutritional Supplement. Japanese J Med Res. 2026; 4(2): 1-4.

ABSTRACT

Background: *Synbiotic supplements that integrate prebiotics, probiotics, and postbiotic substances are progressively utilized to enhance gastrointestinal wellbeing. Colonzak® comprises calcium butyrate, fructo-oligosaccharides (FOS), and two probiotic strains: Bifidobacterium bifidum Bb-06 and Bifidobacterium lactis Bl-04. A thorough safety assessment is necessary to endorse its clinical and consumer application.*

Methods: *A qualitative review was performed utilizing product formulation data, regulatory documents, and published scientific literature. Each component was assessed for toxicological safety, regulatory compliance, and clinical tolerability. Dosage recommendations were evaluated in relation to defined safe intake ranges.*

Results: *All active compounds exhibited robust safety profiles corroborated by EFSA and FDA standards. Calcium butyrate is well tolerated at doses considerably higher than those utilized in Colonzak®. FOS consumption remains well below levels linked to gastrointestinal discomfort.*

Both probiotic strains are listed in the EFSA Qualified Presumption of Safety (QPS) and have been confirmed through clinical research, demonstrating no major side effects. The advised dosage (1–2 capsules per day) is within recognized safe and effective limits.

Conclusion: *Colonzak® is deemed safe for administration in adults and adolescents aged 12 years and older when utilized according to the prescribed guidelines. The formulation aligns with contemporary scientific evidence and regulatory criteria. Longitudinal and population- specific research are advised.*

Keywords

Synbiotic, Butyrate, Bifidobacterium, Safety, Dietary supplement, Fructooligosaccharides (FOS).

Introduction

The human gut microbiota is essential for sustaining gastrointestinal and systemic health. Dysbiosis, characterized by disruptions in microbial balance, has been linked to various illnesses, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), metabolic abnormalities, and immunological dysfunction [1]. Synbiotic formulations—combinations of probiotics and prebiotics—have emerged as a viable approach to restore microbial equilibrium by concurrently providing beneficial bacteria and the substrates essential for their proliferation.

Colonzak® is an innovative synbiotic dietary supplement formulated to enhance intestinal health via a precise amalgamation of three principal elements: calcium butyrate (a short-chain fatty acid), fructo-oligosaccharides (a prebiotic fiber), and two probiotic strains (Bifidobacterium bifidum Bb-06 and Bifidobacterium lactis Bl-04). Butyrate functions as the principal energy substrate for colonocytes and is essential for preserving epithelial barrier integrity [2]. FOS functions as a selective prebiotic, fostering the proliferation of advantageous Bifidobacteria. The chosen probiotic strains directly enhance microbial equilibrium and immunological regulation.

Considering the rising consumption of these supplements by consumers and their prescription by healthcare professionals, a comprehensive, evidence-based assessment of safety and suitable dosage is necessary. This study seeks to evaluate the safety profile and suggested dosage of Colonzak® in accordance with current scientific data and international regulatory standards.

Methodologies

Research Methodology

This study constitutes a qualitative assessment of safety and dose predicated on: manufacturer- supplied product formulation and technical documents; Regulatory information from the European Food Safety Authority (EFSA) and the U.S. Food and Drug Administration (FDA); Peer- reviewed scientific literature sourced from PubMed and Google Scholar.

Sources of Data

Data were acquired from: Clinical and toxicological investigations on butyrate, fructooligosaccharides (FOS), and Bifidobacterium strains have been published; Regulatory safety evaluations (EFSA QPS list, FDA GRAS notifications); Documentation and product specifications from the manufacturer for Colonzak®.

Assessment Standards

Each ingredient was evaluated based on the subsequent criteria:

- Toxicological safety (genotoxicity, carcinogenicity, reproductive toxicity).
- Clinical tolerability derived from human trials.
- Status of regulatory approval.
- Determined secure consumption thresholds.
- Dosage recommendations were assessed in relation to established therapeutic and safety criteria.

Outcomes

Formulation and Dosage

- Each pill of Colonzak® comprises:
- Calcium butyrate – 307 milligrams
- Fructo-oligosaccharides (FOS) – 100 milligrams
- B. bifidum Bb-06 – approximately 1–5 × 10^9 CFU B. lactis Bl-04 – approximately 1 × 10^9 CFU

The suggested daily dosage (1–2 capsules) offers 307–614 mg of calcium butyrate, 100–200 mg of FOS, approximately 2–10 × 10^9 CFU of total probiotics

Safety and Clinical Evidence Regarding Calcium Butyrate

Butyrate is a short-chain fatty acid that is spontaneously synthesized in the colon and serves as a crucial energy source for colonocytes. Clinical research in humans substantiates the tolerance of oral butyrate supplementation. A pilot research including patients with active ulcerative colitis indicated that oral sodium butyrate (1.5 g/day) administered alongside mesalazine was deemed safe and well tolerated [3]. Recent clinical investigations on oral butyrate formulations for gastrointestinal diseases have demonstrated adequate tolerability at doses up to 4 g/day [4], but the majority of published human data pertains to sodium butyrate or mixed formulations rather than exclusively calcium butyrate. EFSA acknowledges butyrate salts as safe food additives. Colonzak™ delivers about 307–614 mg/day of calcium butyrate, resulting in butyrate exposure far lower than the levels examined in clinical studies for oral butyrate therapies.

Safety and Clinical Evidence Regarding Fructo-oligosaccharides (FOS)

FOS are recognized prebiotics with clinical trial evidence demonstrating both bifidogenic properties and favorable gastrointestinal tolerability. They are designated as GRAS (Generally Recognized as Safe) by the FDA [5]. In healthy participants, short-chain fructooligosaccharides elevated fecal bifidobacteria at clinically acceptable levels [6]. A dose-response human investigation indicated that short-chain FOS was bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/day [7]. Gastrointestinal adverse effects (e.g., bloating, gas) are generally noted only at dosages surpassing 10–15 g/day [8]. Colonzak® delivers merely 100–200 mg/day of FOS, which is significantly lower than the gram-level levels often employed in clinical trials and considerably beneath the threshold for harmful effects.

Safety and Clinical Evidence for Bifidobacterium bifidum Bb-06 (ATCC SD6576)

B. bifidum is recognized within the EFSA Qualified Presumption of Safety (QPS) framework at the species level [9]. Human clinical evidence pertinent to the specific strain background associated with Colonzak® is predominantly derived from multistrain formulations that include ATCC SD6576/Bb-06. A randomized triple-blind clinical trial involving obese children and adolescents with nonalcoholic fatty liver disease demonstrated that a probiotic capsule containing B. bifidum ATCC SD6576, among other strains, was linked to enhanced liver-related outcomes after 12 weeks, with no reported safety issues [10]. A separate randomized placebo-controlled trial demonstrated that a probiotic formulation of B. bifidum Bb-06 diminished inflammatory biomarkers and enhanced metabolic parameters in obese people [11]. This research does not delineate the independent action of Bb-06, yet it substantiates the clinical application and tolerability of formulations including this strain.

Safety and Clinical Evidence for Bifidobacterium lactis Bl-04

Bl-04 possesses direct clinical trial evidence in humans affirming its safety. A placebo- controlled human viral-challenge trial

assessed Bifidobacterium animalis subsp. lactis Bl-04 for the prevention of rhinovirus-related illness, yielding strain-specific safety and acceptability data in adults [12]. Further human clinical studies have assessed Bl-04 for skin health outcomes, reaffirming its tolerability [13]. Bl-04 was incorporated into a multi-strain open-label gastrointestinal trial, which indicated satisfactory safety in persons with functional gastrointestinal complaints [14]. No substantial rise in adverse events relative to placebo has been documented in trials with more than 1,500 participants [15,16].

Safety of Excipients

All excipients utilized in the Colonzak® capsule shell and formulation are pharmaceutical-grade compounds cataloged in the FDA Inactive Ingredient Database and are employed within recognized safe limits [17].

Contraindications and Precautions

- According to the assessment, contraindications encompass:
- Individuals below the age of 12 (because to insufficient safety evidence).
- Pregnancy and lactation (because to insufficient safety evidence).
- Documented hypersensitivity to any active or inactive components.

Immunocompromised patients are urged to take precautions and should consult their healthcare physician before to use.

Discussion

This assessment indicates that Colonzak® is a well-balanced synbiotic formulation with a robust safety profile. The amalgamation of butyrate, prebiotics, and probiotics addresses several facets of gastrointestinal health, encompassing epithelial integrity, microbial composition, and metabolic function. The dosage is prudent and conforms to evidence-based parameters that are both secure and potentially efficacious.

Clinical trial data is available for all principal active components of the formulation, however the robustness of evidence varies by constituent. Butyrate and FOS possess substantial human supplementation studies demonstrating tolerance at levels far exceeding those present in Colonzak®. Bl-04 possesses direct, strain-specific clinical evidence derived from numerous randomized controlled trials. B. bifidum Bb-06/ATCC SD6576 is mostly substantiated by multistrain trials incorporating the strain, rather than by distinct, identifiable single-strain randomized controlled trials (RCTs). Nonetheless, no evidence of synergistic toxicity was found among any of the components. Conversely, the components may provide complimentary and perhaps synergistic advantages for gut health.

In comparison to other synbiotic solutions available, Colonzak® delivers moderate yet effective concentrations of active substances while adhering to established safety limits. This careful dosing approach may improve tolerability, especially for patients with sensitive gastrointestinal systems. Nonetheless, akin to the majority of dietary supplements, the long-term safety data are scarce, highlighting a critical subject for further research.

Conclusion

Colonzak® is safe for consumption when administered as prescribed (1–2 capsules daily) in adults and adolescents over the age of 12. All components are underpinned by substantial scientific evidence, clinical trial data, and positive regulatory endorsement from EFSA and FDA guidelines. The advised dosage is comfortably situated within recognized safe and effective parameters.

Subsequent investigations must to concentrate on extended long-term safety investigations above 12 months; clinical efficacy trials in targeted groups (e.g., IBS, IBD, post-antibiotic recovery). Focused safety investigations in pediatric cohorts, during gestation, and in immunocompromised groups.

Funding

This research received funding from the manufacturer of Colonzak®, which did not participate in data analysis or publication creation. Funding Sources: PharmUnion LLC, USA.

References

1. Hill C, Guarner F, Reid G, et al. Expert consensus regarding probiotics. Nature Reviews Gastroenterology & Hepatology. 2014; 11: 506-514.
2. Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol. 2011; 17: 1519-1528.
3. Vernia P, Monteleone G, Grandinetti G, et al. A randomized pilot trial comparing combined oral sodium butyrate and mesalazine treatment with oral mesalazine alone in ulcerative colitis. Dig Liver Dis. 2000; 32: 507-513.
4. Sontag SJ, Sonnenberg A, Edelson MB. Butyrate enemas for the management of ulcerative colitis. American Journal of Gastroenterology. 1999; 94: 1857-1861.
5. Food and Drug Administration (FDA). GRAS Notice No. 800: Fructo-oligosaccharides. 2019.
6. Bouhnik Y, Flourié B, D'Agay-Abensour L, et al. Impact of fructo-oligosaccharides consumption on fecal bifidobacteria and specific metabolic indicators of colon carcinogenesis in healthy individuals. Nutr Cancer. 1996; 26: 21-29.
7. Bouhnik Y, Raskine L, Simoneau G, et al. A study on the dose-response relationship of short-chain fructo-oligosaccharides in stimulating fecal bifidobacteria in healthy individuals. Nutr J. 2006; 5: 8.
8. Biedrzycka E, Bielecka M. Efficacy of fructans as prebiotics. Trends in Food Science & Technology. 2004; 15: 170-175.
9. European Food Safety Authority Biological Hazards Panel. Revision of the QPS list. EFSA Journal. 2021; 19: 6369.
10. Famouri F, Shariat Z, Hashemipour M, et al. Impact of probiotics on nonalcoholic fatty liver disease in obese pediatric and adolescent populations: a randomized clinical trial. J Pediatr Gastroenterol Nutr. 2017; 64: 413-417.

11. Cannarella LAT, de Souza CS, Alberici LC, et al. A combination of probiotics diminishes inflammatory biomarkers and enhances metabolic parameters in obese adults: a randomized, double-blind, placebo-controlled study. Nutrition. 2021; 83: 111091.
12. Turner RB, Woodfolk JA, Borish L, et al. Effect of Bifidobacterium animalis subsp. lactis Bl-04 on rhinovirus-induced colds: a randomized, double-blind, placebo-controlled experiment. American Journal of Clinical Nutrition. 2021; 114: 318-326.
13. Huuskonen L, Jang HJ, Ahn YJ, et al. Investigated the effects of Bifidobacterium animalis subsp. lactis Bl-04 on skin wrinkles and hydration in women by a randomized, triple-blinded, placebo-controlled clinical experiment. J Cosmet Dermatol. 2022; 2: 5.
14. Harris LA, Baffy N, Li X, et al. A multicenter, open-label trial to evaluate the efficacy and safety of a 5-strain probiotic blend in individuals with functional gastrointestinal complaints. GastroHep. 2021; 3: 172-184.
15. Merenstein DJ, Tan TP, Molokin A, et al. Safety of Bifidobacterium animalis subsp. lactis Bl-04. Beneficial Microbes. 2015; 6: 487-493.
16. West NP, Horn PL, Pyne DB, et al. Probiotic supplementation and symptoms of sickness. Clinical Nutrition. 2014; 33: 581-587.
17. Food and Drug Administration (FDA). Inactive Ingredient Database (IID). 2023.